Do economic evaluations of targeted therapy provide support for decision makers?

The American journal of managed care

Volumn 17 Suppl 5 Developing, Issue , 2011, Pages

  Ferrusi, Ilia L ^a   Leighl, Natasha B ^b   Kulin, Nathalie A ^b   Marshall, Deborah A ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; CANADA; COST; DECISION MAKING; ECONOMICS; HUMAN; METHODOLOGY; MOLECULARLY TARGETED THERAPY; REVIEW; UNITED KINGDOM; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CANADA; CHEMOTHERAPY, ADJUVANT; COSTS AND COST ANALYSIS; DECISION MAKING; GREAT BRITAIN; HUMANS; MOLECULAR TARGETED THERAPY; UNITED STATES;

EID: 80155175815     PISSN: None     EISSN: 19362692     Source Type: Journal    
DOI: None     Document Type: Review

References (0)